Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer-Reference-Cited by-同舟云学术

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Published:2020-10-06 Issue:23 Volume:9 Page:8821-8831
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zhao Yannan¹²,Li Yi¹²,Gong Chengcheng¹²,Xie Yizhao¹²,Zhang Jian¹²,Wang Leiping¹²,Cao Jun¹²,Tao Zhonghua¹²,Wang Biyun¹²^ORCID,Hu Xichun¹²

Affiliation:

1. Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai China

2. Department of Oncology Shanghai Medical CollegeFudan University Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3491

Reference25 articles.

1. The natural history of hormone receptor‐positive breast cancer;Lim E;Oncology (Williston Park),2012

2. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

3. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

4. ICI 182,780 (Faslodex?)

5. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer;DeFriend DJ;Cancer Res,1994

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rat Models of Hormone Receptor-Positive Breast Cancer;Journal of Mammary Gland Biology and Neoplasia;2024-06-24

2. Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery;Cancers;2022-11-02

3. A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer;Clinical Oncology;2022-04

4. Fulvestrant;Reactions Weekly;2021-01